Terms: = Prostate cancer AND HLA-A, P01892, 3105, ENSG00000206503, P16188, P30447, P13746, P04439 AND Treatment
19 results:
1. The Prognostic Significance of Selected HLA Alleles on prostate cancer Outcome.
Stokidis S; Baxevanis CN; Fortis SP
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833904
[TBL] [Abstract] [Full Text] [Related]
2. Interferon-γ increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer.
Korentzelos D; Wells A; Clark AM
Sci Rep; 2022 Apr; 12(1):6657. PubMed ID: 35459800
[TBL] [Abstract] [Full Text] [Related]
3. Analysis of Several Pathways for Efficient Killing of prostate cancer Stem Cells: A Central Role of NF-κB RELA.
Witte KE; Pfitzenmaier J; Storm J; Lütkemeyer M; Wimmer C; Schulten W; Czaniera N; Geisler M; Förster C; Wilkens L; Knabbe C; Mertzlufft F; Kaltschmidt B; Am Esch JS; Kaltschmidt C
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445612
[TBL] [Abstract] [Full Text] [Related]
4. Secretome profiling of PC3/nKR cells, a novel highly migrating prostate cancer subline derived from PC3 cells.
Jeon JM; Kwon OK; Na AY; Sung EJ; Cho IJ; Kim M; Yea SS; Chun SY; Lee JH; Ha YS; Kwon TG; Lee S
PLoS One; 2019; 14(8):e0220807. PubMed ID: 31404090
[TBL] [Abstract] [Full Text] [Related]
5. Primary human testicular PDGFRα+ cells are multipotent and can be differentiated into cells with Leydig cell characteristics in vitro.
Eliveld J; van den Berg EA; Chikhovskaya JV; van Daalen SKM; de Winter-Korver CM; van der Veen F; Repping S; Teerds K; van Pelt AMM
Hum Reprod; 2019 Sep; 34(9):1621-1631. PubMed ID: 31398257
[TBL] [Abstract] [Full Text] [Related]
6. Permanent prostate brachytherapy is safe in men with severe baseline lower urinary tract symptoms.
Winoker JS; Say RK; Mehrazin R; Stock RG; Stone NN
Brachytherapy; 2019; 18(3):332-337. PubMed ID: 30890317
[TBL] [Abstract] [Full Text] [Related]
7. A prospective and population-based inquiry on the use and acceptability of peer support for women newly diagnosed with breast cancer.
Legg M; Hyde MK; Occhipinti S; Youl PH; Dunn J; Chambers SK
Support Care Cancer; 2019 Feb; 27(2):677-685. PubMed ID: 30056530
[TBL] [Abstract] [Full Text] [Related]
8. Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer.
Obara W; Sato F; Takeda K; Kato R; Kato Y; Kanehira M; Takata R; Mimata H; Sugai T; Nakamura Y; Fujioka T
Cancer Sci; 2017 Jul; 108(7):1452-1457. PubMed ID: 28498618
[TBL] [Abstract] [Full Text] [Related]
9. Subgroups of Castration-resistant prostate cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
[TBL] [Abstract] [Full Text] [Related]
10. A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that hla-a*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.
Anastasopoulou EA; Voutsas IF; Keramitsoglou T; Gouttefangeas C; Kalbacher H; Thanos A; Papamichail M; Perez SA; Baxevanis CN
Cancer Immunol Immunother; 2015 Sep; 64(9):1123-36. PubMed ID: 26026288
[TBL] [Abstract] [Full Text] [Related]
11. The translation elongation factor eEF2 is a novel tumor‑associated antigen overexpressed in various types of cancers.
Oji Y; Tatsumi N; Fukuda M; Nakatsuka S; Aoyagi S; Hirata E; Nanchi I; Fujiki F; Nakajima H; Yamamoto Y; Shibata S; Nakamura M; Hasegawa K; Takagi S; Fukuda I; Hoshikawa T; Murakami Y; Mori M; Inoue M; Naka T; Tomonaga T; Shimizu Y; Nakagawa M; Hasegawa J; Nezu R; Inohara H; Izumoto S; Nonomura N; Yoshimine T; Okumura M; Morii E; Maeda H; Nishida S; Hosen N; Tsuboi A; Oka Y; Sugiyama H
Int J Oncol; 2014 May; 44(5):1461-9. PubMed ID: 24589652
[TBL] [Abstract] [Full Text] [Related]
12. Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients.
Wilkinson R; Woods K; D'Rozario R; Prue R; Vari F; Hardy MY; Dong Y; Clements JA; Hart DNJ; Radford KJ
Cancer Immunol Immunother; 2012 Feb; 61(2):169-179. PubMed ID: 21874303
[TBL] [Abstract] [Full Text] [Related]
13. Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial.
Brill TH; Kübler HR; Pohla H; Buchner A; Fend F; Schuster T; van Randenborgh H; Paul R; Kummer T; Plank C; Eisele B; Breul J; Hartung R; Schendel DJ; Gansbacher B
Hum Gene Ther; 2009 Dec; 20(12):1641-51. PubMed ID: 19671000
[TBL] [Abstract] [Full Text] [Related]
14. Novel multi-peptide vaccination in hla-a2+ hormone sensitive patients with biochemical relapse of prostate cancer.
Feyerabend S; Stevanovic S; Gouttefangeas C; Wernet D; Hennenlotter J; Bedke J; Dietz K; Pascolo S; Kuczyk M; Rammensee HG; Stenzl A
Prostate; 2009 Jun; 69(9):917-27. PubMed ID: 19267352
[TBL] [Abstract] [Full Text] [Related]
15. HLA typing demands for peptide-based anti-cancer vaccine.
Nagorsen D; Thiel E
Cancer Immunol Immunother; 2008 Dec; 57(12):1903-10. PubMed ID: 18317754
[TBL] [Abstract] [Full Text] [Related]
16. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.
Tamura K; Furihata M; Tsunoda T; Ashida S; Takata R; Obara W; Yoshioka H; Daigo Y; Nasu Y; Kumon H; Konaka H; Namiki M; Tozawa K; Kohri K; Tanji N; Yokoyama M; Shimazui T; Akaza H; Mizutani Y; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
Cancer Res; 2007 Jun; 67(11):5117-25. PubMed ID: 17545589
[TBL] [Abstract] [Full Text] [Related]
17. Practice patterns in screening and management of prostate cancer in elderly men.
Konety BR; Sharp VJ; Verma M; Williams RD;
Urology; 2006 Nov; 68(5):1051-6. PubMed ID: 17095076
[TBL] [Abstract] [Full Text] [Related]
18. Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice.
Machlenkin A; Azriel-Rosenfeld R; Volovitz I; Vadai E; Lev A; Paz A; Goldberger O; Reiter Y; Tzehoval E; Benhar I; Eisenbach L
Cancer Immunol Immunother; 2007 Feb; 56(2):217-26. PubMed ID: 16738849
[TBL] [Abstract] [Full Text] [Related]
19. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.
Fuessel S; Meye A; Schmitz M; Zastrow S; Linné C; Richter K; Löbel B; Hakenberg OW; Hoelig K; Rieber EP; Wirth MP
Prostate; 2006 Jun; 66(8):811-21. PubMed ID: 16482569
[TBL] [Abstract] [Full Text] [Related]
